Exportação concluída — 

MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma

Detalhes bibliográficos
Autor(a) principal: Bergantim, Rui
Data de Publicação: 2025
Outros Autores: Peixoto da Silva, Sara, Pinto, Vanessa, Pereira, Joana M., Sousa, Diana, Trigo, Fernanda, Matthiesen, Rune, Guimarães, José E., Vasconcelos, M. Helena
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Texto Completo: http://hdl.handle.net/10362/182826
Resumo: Funding Information: The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors acknowledge Sociedade Portuguesa de Hematologia/Associa\u00E7\u00E3o Portuguesa contra a Leucemia/AMGEN for funding this work (\u201CBOLSA DE INVESTIGA\u00C7\u00C3O 2017 EM MIELOMA M\u00DALTIPLO\u201D). Funding Information: The authors acknowledge the support of the i3S Bioinformatics Platform, the Flow Cytometry Laboratory of the Clinical Pathology Department, and the Hematology Laboratory of the Clinical Hematology Department of Centro Hospital S\u00E3o Jo\u00E3o, Porto, Portugal. SP is supported by FCT through PhD fellowship 2021.07467. BD. Publisher Copyright: Copyright © 2025 Bergantim, Peixoto da Silva, Pinto, Pereira, Sousa, Trigo, Matthiesen, Guimarães and Vasconcelos.
id RCAP_d75f0538fa94dac3cdaccb94d2cb2721
oai_identifier_str oai:run.unl.pt:10362/182826
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myelomaa preliminary studybiomarkersdrug resistancedrug responsemiRNAsmultiple myelomaPharmacologyPharmacology (medical)Funding Information: The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors acknowledge Sociedade Portuguesa de Hematologia/Associa\u00E7\u00E3o Portuguesa contra a Leucemia/AMGEN for funding this work (\u201CBOLSA DE INVESTIGA\u00C7\u00C3O 2017 EM MIELOMA M\u00DALTIPLO\u201D). Funding Information: The authors acknowledge the support of the i3S Bioinformatics Platform, the Flow Cytometry Laboratory of the Clinical Pathology Department, and the Hematology Laboratory of the Clinical Hematology Department of Centro Hospital S\u00E3o Jo\u00E3o, Porto, Portugal. SP is supported by FCT through PhD fellowship 2021.07467. BD. Publisher Copyright: Copyright © 2025 Bergantim, Peixoto da Silva, Pinto, Pereira, Sousa, Trigo, Matthiesen, Guimarães and Vasconcelos.Background: Multiple myeloma (MM) is a complex hematological malignancy with heterogeneous clinical and pathophysiological backgrounds that influence treatment responses and outcomes. Identifying biomarkers to predict drug response and guide treatment decisions, particularly regarding drug combinations, is essential to improve therapeutic efficacy and patient outcomes. This study explores the role of microRNAs (miRNAs/miRs) derived from bone marrow (BM) and peripheral blood (PB) in responses to treatment and survival outcomes in newly diagnosed MM (ndMM) patients. Methods: This study included twenty patients with ndMM undergoing first-line treatment with bortezomib, thalidomide, and dexamethasone. The miRNAs were isolated from BM and PB, and their profiles were analyzed using Next-Generation Sequencing (NGS), followed by validation of differentially expressed miRNAs by quantitative real-time PCR (qPCR). Clinical and response data were collected to assess correlations between miRNA levels, clinical characteristics, and patient outcomes. In silico analysis for target-prediction and gene ontology (GO) enrichment was performed to explore the potential biological and functional role of the identified miRNAs. Results: NGS profiling revealed several miRNAs differently expressed between treatment-refractory and sensitive patients, as well as between PB and BM. Among these, miR-665, miR-483-5p, miR-143-3p and miR-145-5p were selected for further validation by qPCR. It was observed that miR-665 was significantly elevated in treatment-refractory patients compared to treatment-sensitive patients. Additionally, miR-665 levels were higher in PB than in BM. Elevated miR-665 levels were associated with more aggressive disease characteristics and poorer clinical outcomes, including reduced overall survival. Discussion: Our preliminary findings suggest that miR-665 could potentially serve as a non-invasive tool for predicting drug resistance and guiding treatment decisions in MM. These findings also highlight the potential utility of miRNAs in liquid biopsies as a predictive tool of drug response in MM and could pave the way for personalized treatment strategies, improving patient outcomes. Future research is needed to validate these results in larger cohorts and explore the underlying mechanisms of miR-665 in MM pathogenesis and drug resistance.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)iNOVA4Health - pólo NMSRUNBergantim, RuiPeixoto da Silva, SaraPinto, VanessaPereira, Joana M.Sousa, DianaTrigo, FernandaMatthiesen, RuneGuimarães, José E.Vasconcelos, M. Helena2025-05-07T21:35:08Z2025-042025-04-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/182826eng1663-9812PURE: 115627998https://doi.org/10.3389/fphar.2025.1465814info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-05-19T01:40:09Zoai:run.unl.pt:10362/182826Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T07:13:51.225586Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma
a preliminary study
title MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma
spellingShingle MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma
Bergantim, Rui
biomarkers
drug resistance
drug response
miRNAs
multiple myeloma
Pharmacology
Pharmacology (medical)
title_short MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma
title_full MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma
title_fullStr MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma
title_full_unstemmed MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma
title_sort MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma
author Bergantim, Rui
author_facet Bergantim, Rui
Peixoto da Silva, Sara
Pinto, Vanessa
Pereira, Joana M.
Sousa, Diana
Trigo, Fernanda
Matthiesen, Rune
Guimarães, José E.
Vasconcelos, M. Helena
author_role author
author2 Peixoto da Silva, Sara
Pinto, Vanessa
Pereira, Joana M.
Sousa, Diana
Trigo, Fernanda
Matthiesen, Rune
Guimarães, José E.
Vasconcelos, M. Helena
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
iNOVA4Health - pólo NMS
RUN
dc.contributor.author.fl_str_mv Bergantim, Rui
Peixoto da Silva, Sara
Pinto, Vanessa
Pereira, Joana M.
Sousa, Diana
Trigo, Fernanda
Matthiesen, Rune
Guimarães, José E.
Vasconcelos, M. Helena
dc.subject.por.fl_str_mv biomarkers
drug resistance
drug response
miRNAs
multiple myeloma
Pharmacology
Pharmacology (medical)
topic biomarkers
drug resistance
drug response
miRNAs
multiple myeloma
Pharmacology
Pharmacology (medical)
description Funding Information: The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors acknowledge Sociedade Portuguesa de Hematologia/Associa\u00E7\u00E3o Portuguesa contra a Leucemia/AMGEN for funding this work (\u201CBOLSA DE INVESTIGA\u00C7\u00C3O 2017 EM MIELOMA M\u00DALTIPLO\u201D). Funding Information: The authors acknowledge the support of the i3S Bioinformatics Platform, the Flow Cytometry Laboratory of the Clinical Pathology Department, and the Hematology Laboratory of the Clinical Hematology Department of Centro Hospital S\u00E3o Jo\u00E3o, Porto, Portugal. SP is supported by FCT through PhD fellowship 2021.07467. BD. Publisher Copyright: Copyright © 2025 Bergantim, Peixoto da Silva, Pinto, Pereira, Sousa, Trigo, Matthiesen, Guimarães and Vasconcelos.
publishDate 2025
dc.date.none.fl_str_mv 2025-05-07T21:35:08Z
2025-04
2025-04-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/182826
url http://hdl.handle.net/10362/182826
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1663-9812
PURE: 115627998
https://doi.org/10.3389/fphar.2025.1465814
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833602925611450368